Percheron Therapeutics Limited

CHIA:PER Stock Report

Market Cap: AU$78.4m

Percheron Therapeutics Valuation

Is PER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PER's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PER's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PER?

Key metric: As PER is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PER. This is calculated by dividing PER's market cap by their current revenue.
What is PER's PS Ratio?
PS Ratio26.4x
SalesAU$2.97m
Market CapAU$78.44m

Price to Sales Ratio vs Peers

How does PER's PS Ratio compare to its peers?

The above table shows the PS ratio for PER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.2x
VIT Vitura Health
0.5xn/aAU$57.0m
RCE Recce Pharmaceuticals
21.7x-1.8%AU$106.7m
SPL Starpharma Holdings
4.9xn/aAU$48.0m
LGP Little Green Pharma
1.6x16.3%AU$39.2m
PER Percheron Therapeutics
26.4x45.3%AU$78.4m

Price-To-Sales vs Peers: PER is expensive based on its Price-To-Sales Ratio (26.4x) compared to the peer average (7x).

Price to Sales Ratio vs Industry

How does PER's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

16 CompaniesPrice / SalesEstimated GrowthMarket Cap
MYX Mayne Pharma Group
1x11.3%US$236.25m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.5xn/aUS$76.10m
VIT Vitura Health
0.5xn/aUS$37.04m
PER 26.4xIndustry Avg. 4.9xNo. of Companies16PS01224364860+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PER is expensive based on its Price-To-Sales Ratio (26.4x) compared to the Australian Pharmaceuticals industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is PER's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PER PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26.4x
Fair PS Ratio11.5x

Price-To-Sales vs Fair Ratio: PER is expensive based on its Price-To-Sales Ratio (26.4x) compared to the estimated Fair Price-To-Sales Ratio (11.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.075
AU$0.21
+180.0%
23.7%AU$0.25AU$0.14n/a3
Nov ’25AU$0.079
AU$0.22
+174.3%
25.7%AU$0.27AU$0.14n/a3
Oct ’25AU$0.10
AU$0.22
+106.4%
25.7%AU$0.27AU$0.14n/a3
Sep ’25AU$0.086
AU$0.22
+151.9%
25.7%AU$0.27AU$0.14n/a3
Aug ’25AU$0.072
AU$0.21
+196.3%
25.5%AU$0.27AU$0.14n/a3
Jul ’25AU$0.08
AU$0.25
+212.5%
8.0%AU$0.27AU$0.23n/a2
Jun ’25AU$0.081
AU$0.25
+208.6%
8.0%AU$0.27AU$0.23n/a2
May ’25AU$0.072
AU$0.25
+247.2%
8.0%AU$0.27AU$0.23n/a2
Apr ’25AU$0.082
AU$0.25
+204.9%
8.0%AU$0.27AU$0.23n/a2
Mar ’25AU$0.09
AU$0.25
+177.8%
8.0%AU$0.27AU$0.23n/a2
Feb ’25AU$0.06
AU$0.25
+316.7%
8.0%AU$0.27AU$0.23n/a2
Jan ’25AU$0.059
AU$0.27
+349.2%
13.2%AU$0.30AU$0.23n/a2
Dec ’24AU$0.06
AU$0.27
+341.7%
13.2%AU$0.30AU$0.23n/a2
Nov ’24AU$0.057
AU$0.27
+364.9%
13.2%AU$0.30AU$0.23AU$0.0792
Oct ’24AU$0.069
AU$0.27
+284.1%
13.2%AU$0.30AU$0.23AU$0.102
Sep ’24AU$0.06
AU$0.27
+341.7%
13.2%AU$0.30AU$0.23AU$0.0862
Aug ’24AU$0.054
AU$0.28
+413.8%
7.1%AU$0.30AU$0.26AU$0.0722
Jul ’24AU$0.062
AU$0.31
+400.0%
16.1%AU$0.36AU$0.26AU$0.082
Jun ’24AU$0.06
AU$0.31
+416.7%
16.1%AU$0.36AU$0.26AU$0.0812
May ’24AU$0.076
AU$0.31
+307.9%
16.1%AU$0.36AU$0.26AU$0.0722
Apr ’24AU$0.094
AU$0.31
+229.8%
16.1%AU$0.36AU$0.26AU$0.0822
Mar ’24AU$0.098
AU$0.31
+216.3%
16.1%AU$0.36AU$0.26AU$0.092
Feb ’24AU$0.09
AU$0.31
+244.4%
16.1%AU$0.36AU$0.26AU$0.062
Jan ’24AU$0.093
AU$0.31
+233.3%
16.1%AU$0.36AU$0.26AU$0.0592
Dec ’23AU$0.087
AU$0.31
+256.3%
16.1%AU$0.36AU$0.26AU$0.062
Nov ’23AU$0.085
AU$0.31
+264.7%
16.1%AU$0.36AU$0.26AU$0.0572

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

7D

8.0%

1Y

10.2%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.41

7D

-3.5%

1Y

-47.1%

AVITA Medical

US$349.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$4.20

7D

12.6%

1Y

27.7%